Analysts Set Biogen Inc. (NASDAQ:BIIB) PT at $182.48

Shares of Biogen Inc. (NASDAQ:BIIB) have earned an average rating of “Hold” from the twenty-five ratings firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, fourteen have given a hold recommendation and ten have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $182.48.

A number of equities research analysts have recently issued reports on BIIB shares. William Blair reiterated an “outperform” rating on shares of Biogen in a research report on Wednesday, September 24th. Stifel Nicolaus raised Biogen from a “hold” rating to a “buy” rating and raised their price objective for the company from $144.00 to $202.00 in a research note on Thursday, November 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Biogen in a research report on Monday. HSBC reissued a “reduce” rating and issued a $143.00 target price (down previously from $144.00) on shares of Biogen in a report on Wednesday, December 10th. Finally, Guggenheim lifted their price target on Biogen from $165.00 to $185.00 in a research note on Friday, October 31st.

Biogen Trading Down 2.4%

NASDAQ:BIIB opened at $171.50 on Friday. Biogen has a 1 year low of $110.04 and a 1 year high of $185.17. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.04 and a current ratio of 2.72. The stock has a fifty day moving average price of $162.26 and a two-hundred day moving average price of $144.53. The stock has a market capitalization of $25.16 billion, a price-to-earnings ratio of 15.63, a PEG ratio of 1.48 and a beta of 0.13.

Biogen (NASDAQ:BIIB) last issued its earnings results on Thursday, October 30th. The biotechnology company reported $4.81 EPS for the quarter, topping the consensus estimate of $3.89 by $0.92. The company had revenue of $2.53 billion for the quarter, compared to analyst estimates of $2.34 billion. Biogen had a net margin of 15.98% and a return on equity of 14.13%. The business’s revenue was up 2.8% on a year-over-year basis. During the same period in the previous year, the firm earned $4.08 EPS. Biogen has set its FY 2025 guidance at 14.500-15.00 EPS. As a group, sell-side analysts anticipate that Biogen will post 15.83 earnings per share for the current fiscal year.

Institutional Trading of Biogen

Several large investors have recently modified their holdings of BIIB. Allworth Financial LP increased its holdings in shares of Biogen by 30.3% during the 3rd quarter. Allworth Financial LP now owns 2,840 shares of the biotechnology company’s stock worth $398,000 after buying an additional 661 shares during the last quarter. CIBC Private Wealth Group LLC grew its position in Biogen by 8.1% during the third quarter. CIBC Private Wealth Group LLC now owns 1,189 shares of the biotechnology company’s stock valued at $167,000 after acquiring an additional 89 shares during the period. CIBC Bancorp USA Inc. purchased a new stake in Biogen during the third quarter valued at about $3,585,000. Caerus Investment Advisors LLC acquired a new stake in Biogen during the third quarter worth about $347,000. Finally, Captrust Financial Advisors raised its holdings in shares of Biogen by 13.3% in the 3rd quarter. Captrust Financial Advisors now owns 16,532 shares of the biotechnology company’s stock worth $2,316,000 after purchasing an additional 1,937 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.